Loading...
•
Dec 26, 2020
Hologic Q1 2021 Earnings Report
Hologic had a strong start to fiscal 2021, driven by Diagnostics division and strengthened Breast Health and Surgical businesses.
Key Takeaways
Hologic's Q1 2021 revenue reached $1.61 billion, an 89.3% increase year-over-year, driven by strong performance in the Diagnostics division and growth in Breast Health and Surgical businesses. The company reported GAAP diluted EPS of $2.50 and non-GAAP diluted EPS of $2.86.
Revenue increased by 89.3% to $1.61 billion, with constant currency increase of 86.5%.
Organic revenue increased by 107.0%, or 104.0% in constant currency.
Worldwide molecular diagnostics revenue increased 457.6% to $995.3 million.
Cash flow from operations was $650.0 million, leading to debt repayment and stock repurchases.
Hologic
Hologic
Hologic Revenue by Segment
Hologic Revenue by Geographic Location
Revenue by Segment
Diagnostics Revenue
CapyFin.comMolecular Diagnostics Revenue
CapyFin.comBreast Health Revenue
CapyFin.comBreast Imaging Revenue
CapyFin.comInterventional Breast Solutions Revenue
CapyFin.comGYN Surgical Revenue
CapyFin.comSkeletal Health Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
Hologic expects strong financial performance to continue in the second quarter of fiscal 2021.
Positive Outlook
- Revenue is expected to be between $1,500 million and $1,560 million.
- Reported revenue increase is projected to be between 98.4% and 106.3%.
- Constant currency revenue increase is expected to be between 93.9% and 101.9%.
- Organic revenue increase is forecasted to be between 96.2% and 104.3%.
- Non-GAAP EPS is expected to be between $2.56 and $2.68.
Revenue & Expenses
Visualization of income flow from segment revenue to net income